Regulus Therapeutics Inc. (RGLS)
Regulus Therapeutics Statistics
Share Statistics
Regulus Therapeutics has 66.24M shares outstanding. The number of shares has increased by 1.19% in one year.
| Shares Outstanding | 66.24M |
| Shares Change (YoY) | 1.19% |
| Shares Change (QoQ) | 1.13% |
| Owned by Institutions (%) | 81.73% |
| Shares Floating | 53.18M |
| Failed to Deliver (FTD) Shares | 984 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 1.76M, so 2.69% of the outstanding shares have been sold short.
| Short Interest | 1.76M |
| Short % of Shares Out | 2.69% |
| Short % of Float | 3.34% |
| Short Ratio (days to cover) | 5.51 |
Valuation Ratios
The PE ratio is -1.92 and the forward PE ratio is -0.71. Regulus Therapeutics's PEG ratio is 0.04.
| PE Ratio | -1.92 |
| Forward PE | -0.71 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 1.17 |
| P/FCF Ratio | -2.12 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Regulus Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.98, with a Debt / Equity ratio of 0.
| Current Ratio | 10.98 |
| Quick Ratio | 10.98 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | -316.71 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.36M |
| Employee Count | 34 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -36.03% in the last 52 weeks. The beta is 1.41, so Regulus Therapeutics's price volatility has been higher than the market average.
| Beta | 1.41 |
| 52-Week Price Change | -36.03% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 1.55 |
| Relative Strength Index (RSI) | 67.53 |
| Average Volume (20 Days) | 1.08M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -50.04M |
| Net Income | -46.36M |
| EBITDA | -45.85M |
| EBIT | -46.2M |
| Earnings Per Share (EPS) | -0.82 |
Balance Sheet
The company has 38.53M in cash and 274K in debt, giving a net cash position of 38.25M.
| Cash & Cash Equivalents | 38.53M |
| Total Debt | 274K |
| Net Cash | 38.25M |
| Retained Earnings | -559.57M |
| Total Assets | 84.18M |
| Working Capital | 74.85M |
Cash Flow
In the last 12 months, operating cash flow was -41.67M and capital expenditures -340K, giving a free cash flow of -42.01M.
| Operating Cash Flow | -41.67M |
| Capital Expenditures | -340K |
| Free Cash Flow | -42.01M |
| FCF Per Share | -0.75 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RGLS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RGLS is $7.5, which is 331% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.5 |
| Price Target Difference | 331% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Jun 29, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 29, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -1.1 |
| Piotroski F-Score | 2 |